Glenmark Pharmaceuticals Limited has divested its active pharmaceutical ingredients (API) business to the diversified Indian group Nirma Limited for INR56.51bn ($681m), ending long-running speculation of an imminent deal.
In a late evening announcement on 21 September, Glenmark said it had struck a definitive agreement with Nirma to sell...